| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A Case Study of the Incremental Utility for Disease Identification of Natural Language Processing in Electronic Medical Records
|
Weiss, Lisa S.
|
|
2017
|
|
1 |
p. 31-37
|
artikel
|
| 2 |
Accreditation Standards for Medical Science Liaison (MSL) Certification Programmes in Japan: A Viewpoint from the Japanese Association of Pharmaceutical Medicine (JAPhMED)
|
Uchida, Ichiro
|
|
2015
|
|
1 |
p. 23-35
|
artikel
|
| 3 |
A Comparison of Methods for Thorough QT Analysis for the Assessment of Cardiac Safety
|
Ferber, Georg
|
|
2015
|
|
1 |
p. 15-21
|
artikel
|
| 4 |
A Descriptive Study of Additional Risk Minimization Measures Included in Risk Management Plans Reviewed by the United Kingdom Regulatory Authority
|
Keddie, Sophie
|
|
2013
|
|
1 |
p. 25-34
|
artikel
|
| 5 |
Adverse Drug Reactions Involving Protein Kinase Inhibitors: A French Pharmacovigilance Database Study Comparing Safety in Younger and Older Patients (≥ 75 years) with Cancer
|
Clapes, Vincent
|
|
2018
|
|
1 |
p. 21-27
|
artikel
|
| 6 |
A European Conference on Clinical Research in Children: ethical, scientific and regulatory issues
|
Smith, Robert N.
|
|
|
|
1 |
p. 15-24
|
artikel
|
| 7 |
Analysis of the Factors Influencing the Spontaneous Reporting Frequency of Drug Safety Issues Addressed in the FDA’s Drug Safety Communications, Using FAERS Data
|
Ishiguro, Chieko
|
|
2014
|
|
1 |
p. 7-19
|
artikel
|
| 8 |
Assessing the Arrhythmogenic Potential of New Drugs: A Guide for the Pharmaceutical Physician
|
Gunaruwan, Prasad
|
|
2015
|
|
1 |
p. 11-16
|
artikel
|
| 9 |
Assessment of a Severity-Based Algorithm to Detect Signals of Severe Drug-Induced Liver Injury Using Spontaneous Reporting Database
|
Gupte-Singh, Komal
|
|
2016
|
|
1 |
p. 41-51
|
artikel
|
| 10 |
Austria
|
|
|
2007
|
|
1 |
p. 3-6
|
artikel
|
| 11 |
Automation Opportunities in Pharmacovigilance: An Industry Survey
|
Ghosh, Rajesh
|
|
|
|
1 |
p. 7-18
|
artikel
|
| 12 |
Belgium
|
|
|
2007
|
|
1 |
p. 7-10
|
artikel
|
| 13 |
Benefit Risk Management Plans?
|
Blackburn, Stella C. F.
|
|
2012
|
|
1 |
p. 5-8
|
artikel
|
| 14 |
Biosimilars in the USA: Will New Efforts to Spur Approvals and Access Spur Uptake and Cost Savings?
|
Mehr, Stanton R.
|
|
2019
|
|
1 |
p. 1-8
|
artikel
|
| 15 |
Characterization of the Recent Postmarketing Safety Measures in Europe Focusing on Additional Pharmacovigilance Activities
|
Iwasaki, Mami
|
|
2017
|
|
1 |
p. 31-39
|
artikel
|
| 16 |
Clinically Relevant Drug-Drug and Drug-Food Interactions
|
Brewer, Linda
|
|
2013
|
|
1 |
p. 9-23
|
artikel
|
| 17 |
Clinical Trial Regulations in India: Progress and Challenges Arising from Recent Amendments to Schedule Y of the Drugs and Cosmetics (D&C) Act 1940 (D&C Rules 1945)
|
Kondal, Amit
|
|
2015
|
|
1 |
p. 1-13
|
artikel
|
| 18 |
Clinical Trials Using Mobile Health Applications
|
LoPresti, Melissa A.
|
|
2015
|
|
1 |
p. 17-25
|
artikel
|
| 19 |
Combined Liquid Chromatography-mass Spectrometry and Next-generation DNA Sequencing Detection of Adulterants and Contaminants in Analgesic and Anti-inflammatory Herbal Medicines
|
Hoban, Claire L.
|
|
|
|
1 |
p. 49-61
|
artikel
|
| 20 |
Comparative Effectiveness Research in the Regulatory Setting
|
Siegel, Jay P.
|
|
2012
|
|
1 |
p. 5-11
|
artikel
|
| 21 |
Correction to: Adverse Drug Reaction Case Safety Practices in Large Biopharmaceutical Organizations from 2007 to 2017: An Industry Survey
|
Stergiopoulos, Stella
|
|
|
|
1 |
p. 81
|
artikel
|
| 22 |
Cyprus
|
|
|
2007
|
|
1 |
p. 11-14
|
artikel
|
| 23 |
Czech Republic
|
|
|
2007
|
|
1 |
p. 15-17
|
artikel
|
| 24 |
Denmark
|
|
|
2007
|
|
1 |
p. 19-22
|
artikel
|
| 25 |
Development of Post-Marketing Risk Management Plan Requirements: The Singapore Experience
|
Tan, Liesbet Li-Bei
|
|
2017
|
|
1 |
p. 13-20
|
artikel
|
| 26 |
DNA Vaccines
|
Srivastava, Indresh K.
|
|
|
|
1 |
p. 15-28
|
artikel
|
| 27 |
Do Molecular Structures of Migraine Drugs Point to a Common Cause of this Elusive Disease and Suggest Future Drug Designs?
|
Brinsden, Mark J.
|
|
2015
|
|
1 |
p. 1-5
|
artikel
|
| 28 |
Drugs in Clinical Development for Major Depressive Disorder
|
|
|
2013
|
|
1 |
p. 35-42
|
artikel
|
| 29 |
Drugs in Clinical Development for Malignant Melanoma: Summary and Table
|
|
|
2015
|
|
1 |
p. 27-49
|
artikel
|
| 30 |
Drugs in Clinical Development for Tuberculosis: Summary and Table
|
|
|
2014
|
|
1 |
p. 21-24
|
artikel
|
| 31 |
Drugs in Clinical Development for Type 2 Diabetes Mellitus
|
|
|
2012
|
|
1 |
p. 27-43
|
artikel
|
| 32 |
Early Trial Discontinuation in Toxicity-Driven, Dose-Escalating, Phase I Cancer Trials: Occurrence, Outcomes and Predictive Factors
|
Cousin, Sophie
|
|
2015
|
|
1 |
p. 49-55
|
artikel
|
| 33 |
Effective Market Exclusivity of New Molecular Entities for Rare and Non-rare Diseases
|
Kerr, Kirk W.
|
|
|
|
1 |
p. 19-29
|
artikel
|
| 34 |
Estonia
|
|
|
2007
|
|
1 |
p. 23-26
|
artikel
|
| 35 |
Evaluation of the US Food and Drug Administration Sentinel Analysis Tools Using a Comparator with a Different Indication: Comparing the Rates of Gastrointestinal Bleeding in Warfarin and Statin Users
|
Carnahan, Ryan M.
|
|
2019
|
|
1 |
p. 29-43
|
artikel
|
| 36 |
Factors Influencing the Generation of Evidence from Simple Data Held in International Rare Disease Patient Registries
|
Jandhyala, Ravi
|
|
|
|
1 |
p. 31-38
|
artikel
|
| 37 |
Factors that Motivate Healthcare Professionals to Report Adverse Drug Events: A Systematic Review
|
Abjaude, Samir Antonio Rodrigues
|
|
2016
|
|
1 |
p. 13-20
|
artikel
|
| 38 |
Finland
|
|
|
2007
|
|
1 |
p. 27-30
|
artikel
|
| 39 |
Forum
|
|
|
2014
|
|
1 |
p. 25-34
|
artikel
|
| 40 |
Forum
|
|
|
2016
|
|
1 |
p. 53-67
|
artikel
|
| 41 |
Forum
|
|
|
2018
|
|
1 |
p. 67-87
|
artikel
|
| 42 |
Forum
|
|
|
2015
|
|
1 |
p. 57-65
|
artikel
|
| 43 |
Forum
|
|
|
2013
|
|
1 |
p. 43-51
|
artikel
|
| 44 |
Forum
|
|
|
2012
|
|
1 |
p. 49-61
|
artikel
|
| 45 |
Forum
|
|
|
2015
|
|
1 |
p. 51-62
|
artikel
|
| 46 |
Forum
|
|
|
2019
|
|
1 |
p. 63-78
|
artikel
|
| 47 |
Forum
|
|
|
|
|
1 |
p. 63-75
|
artikel
|
| 48 |
France
|
|
|
2007
|
|
1 |
p. 31-33
|
artikel
|
| 49 |
Germany
|
|
|
2007
|
|
1 |
p. 35-38
|
artikel
|
| 50 |
Gini Index-Based Maximum Concentration and Area Under the Curve Split Points for Analysing Adverse Event Occurrence in Bioequivalence Studies
|
Torres-García, Blanca L.
|
|
2017
|
|
1 |
p. 51-66
|
artikel
|
| 51 |
Greece
|
|
|
2007
|
|
1 |
p. 39-41
|
artikel
|
| 52 |
Hungary
|
|
|
2007
|
|
1 |
p. 43-46
|
artikel
|
| 53 |
International Comparison of Five Herbal Medicine Registration Systems to Inform Regulation Development: United Kingdom, Germany, United States of America, United Arab Emirates and Kingdom of Bahrain
|
Alostad, Azhar H.
|
|
2018
|
|
1 |
p. 39-49
|
artikel
|
| 54 |
Ireland
|
|
|
2007
|
|
1 |
p. 47-50
|
artikel
|
| 55 |
Italy
|
|
|
2007
|
|
1 |
p. 51-53
|
artikel
|
| 56 |
ITS2: An Ideal DNA Barcode for the Arid Medicinal Plant Rhazya Stricta
|
Khan, Samia A.
|
|
2019
|
|
1 |
p. 53-61
|
artikel
|
| 57 |
Journal Watch
|
|
|
2014
|
|
1 |
p. 35-45
|
artikel
|
| 58 |
Journal Watch
|
|
|
2012
|
|
1 |
p. 63-72
|
artikel
|
| 59 |
Journal Watch
|
|
|
2013
|
|
1 |
p. 53-67
|
artikel
|
| 60 |
Latvia
|
|
|
2007
|
|
1 |
p. 55-57
|
artikel
|
| 61 |
Lithuania
|
|
|
2007
|
|
1 |
p. 59-63
|
artikel
|
| 62 |
Major Pharmaceutical Conferences and Courses
|
|
|
2014
|
|
1 |
p. 47-51
|
artikel
|
| 63 |
Major Pharmaceutical Conferences and Courses
|
|
|
2016
|
|
1 |
p. 69-73
|
artikel
|
| 64 |
Major Pharmaceutical Conferences and Courses
|
|
|
2018
|
|
1 |
p. 89-91
|
artikel
|
| 65 |
Major Pharmaceutical Conferences and Courses
|
|
|
2015
|
|
1 |
p. 67-70
|
artikel
|
| 66 |
Major Pharmaceutical Conferences and Courses
|
|
|
2013
|
|
1 |
p. 69-73
|
artikel
|
| 67 |
Major Pharmaceutical Conferences and Courses
|
|
|
2012
|
|
1 |
p. 73-75
|
artikel
|
| 68 |
Major Pharmaceutical Conferences and Courses
|
|
|
2015
|
|
1 |
p. 63-67
|
artikel
|
| 69 |
Major Pharmaceutical Conferences and Courses
|
|
|
2019
|
|
1 |
p. 79-82
|
artikel
|
| 70 |
Major Pharmaceutical Conferences and Courses
|
|
|
|
|
1 |
p. 77-80
|
artikel
|
| 71 |
Making the Proper Choices on Education for the Pharmaceutical Industry
|
Naraynassamy, Carl
|
|
2015
|
|
1 |
p. 7-10
|
artikel
|
| 72 |
Malta
|
|
|
2007
|
|
1 |
p. 65-68
|
artikel
|
| 73 |
Methodological Issues in the Design of Paediatric Pharmacokinetic Studies
|
Burckart, Gilbert J.
|
|
2012
|
|
1 |
p. 13-22
|
artikel
|
| 74 |
New Financial and Research Models for Pediatric Orphan Drug Development: Focus on the NCATS TRND Program
|
Shen, John
|
|
2014
|
|
1 |
p. 1-6
|
artikel
|
| 75 |
News from member associations
|
Collia, Luis
|
|
|
|
1 |
p. 45-49
|
artikel
|
| 76 |
Norway
|
|
|
2007
|
|
1 |
p. 73-75
|
artikel
|
| 77 |
Patient Engagement in Medical Device Design: Refining the Essential Attributes of a Wearable, Pre-Void, Ultrasound Alarm for Nocturnal Enuresis
|
Caswell, Noreen
|
|
|
|
1 |
p. 39-48
|
artikel
|
| 78 |
Peptide-Based Therapeutics for Oncology
|
Fisher, Elizaveta
|
|
2019
|
|
1 |
p. 9-20
|
artikel
|
| 79 |
Pharmaceutical Sector Development in Africa: Progress to Date
|
Lartey, Paul A.
|
|
2018
|
|
1 |
p. 1-11
|
artikel
|
| 80 |
Pharmacovigilance in Qatar Hospitals
|
Wilbur, Kerry
|
|
2012
|
|
1 |
p. 23-25
|
artikel
|
| 81 |
Pharmacovigilance: Work in Progress
|
Beninger, Paul
|
|
2016
|
|
1 |
p. 1-5
|
artikel
|
| 82 |
Phase III ATENA Trial of Exemestane Discontinued
|
Sweetlove, Mel
|
|
2012
|
|
1 |
p. 45-47
|
artikel
|
| 83 |
Poland
|
|
|
2007
|
|
1 |
p. 77-80
|
artikel
|
| 84 |
Portugal
|
|
|
2007
|
|
1 |
p. 81-83
|
artikel
|
| 85 |
Potential Procedural Efficiencies and Challenges of Combining Multiple Type II Variations into a Single EU-RMP
|
Marshall, Ryan
|
|
|
|
1 |
p. 1-5
|
artikel
|
| 86 |
Publisher Correction: Cardiovascular Outcome Trials of Diabetes and Obesity Drugs: Implications for Conditional Approval and Early Phase Clinical Development
|
Krentz, Andrew J.
|
|
2018
|
|
1 |
p. 93
|
artikel
|
| 87 |
Safety-Related Regulatory Actions and Risk Factors for Anticancer Drugs in Japan
|
Nakayama, Hiroki
|
|
2018
|
|
1 |
p. 45-52
|
artikel
|
| 88 |
Size and Taste Matters: Recent Progress in the Development of Age-Appropriate Medicines for Children
|
Rieder, Michael
|
|
2017
|
|
1 |
p. 21-30
|
artikel
|
| 89 |
Slovak Republic
|
|
|
2007
|
|
1 |
p. 85-88
|
artikel
|
| 90 |
Slovenia
|
|
|
2007
|
|
1 |
p. 89-91
|
artikel
|
| 91 |
Spain
|
|
|
2007
|
|
1 |
p. 93-95
|
artikel
|
| 92 |
Sweden
|
|
|
2007
|
|
1 |
p. 97-99
|
artikel
|
| 93 |
Switzerland
|
|
|
2007
|
|
1 |
p. 101-104
|
artikel
|
| 94 |
The Great Indian Medicine Man
|
Rowe, Raymond C.
|
|
|
|
1 |
p. 33-35
|
artikel
|
| 95 |
The Jordan Food and Drug Administration: Comparison of its Registration Process with Australia, Canada, Saudi Arabia and Singapore
|
Haqaish, Wesal Salem Al
|
|
2016
|
|
1 |
p. 21-30
|
artikel
|
| 96 |
The Netherlands
|
|
|
2007
|
|
1 |
p. 69-72
|
artikel
|
| 97 |
The Pharmaceutical Medicine Year that Was, 2011
|
Fox, Anthony W.
|
|
2012
|
|
1 |
p. 1-3
|
artikel
|
| 98 |
The Pharmaceutical Medicine Year that Was, 2012
|
Fox, Anthony W.
|
|
2013
|
|
1 |
p. 1-3
|
artikel
|
| 99 |
The Saudi Arabia Food and Drug Authority: An Evaluation of the Registration Process and Good Review Practices in Saudi Arabia in Comparison with Australia, Canada and Singapore
|
Hashan, Hajed
|
|
2015
|
|
1 |
p. 37-47
|
artikel
|
| 100 |
12th International Conference On Pharmaceutical Medicine: The Future is Now
|
|
|
|
|
1 |
p. 31-41
|
artikel
|
| 101 |
United Kingdom
|
|
|
2007
|
|
1 |
p. 105-110
|
artikel
|
| 102 |
US Prescription Drug User Fee Act (PDUFA): An Introduction for the Pharmaceutical Physician
|
Mullin, Theresa M.
|
|
2016
|
|
1 |
p. 7-12
|
artikel
|
Tijdschrift beschrijving